The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,296.00
Bid: 12,322.00
Ask: 12,324.00
Change: -108.00 (-0.87%)
Spread: 2.00 (0.016%)
Open: 12,334.00
High: 12,362.00
Low: 12,250.00
Prev. Close: 12,404.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: UK Stocks Fall As US GDP Surge Turns Attention To Fed

Wed, 30th Jul 2014 16:34

LONDON (Alliance News) - UK stocks had a choppy trading session Wednesday and ultimately closed lower, while the dollar gained against other major currencies, as some heavily anticipated US GDP data showed the world's biggest economy more than reversed its first quarter slump.

The surprisingly strong US economy shifted the market focus squarely onto the Federal Reserve policy announcement still to come Wednesday.

The US economy grew at an annualised rate of 4.0% in the second quarter, more than reversing the 2.1% contraction in the first quarter, which was also revised up from the original 2.9% drop.

The data has been a long time coming for a market hoping for a sharp reversal in US economic growth following the first-quarter contraction, which was broadly blamed on particularly harsh winter weather. However, despite the reading causing an initial surge in global equity markets to session highs, investors have since reverted to caution ahead of a potential change of tone from the Federal Open Market Committee announcement at 1900 BST.

Concern over the potential economic impact of new sanctions from the EU and the US against Russia also have continued to weigh on general sentiment, and particularly the energy sector.

The FTSE 100 closed down 0.5% at 6,773.44 and the FTSE 250 down 0.4% at 15,629.84, while the AIM All-Share outperformed, closing up 0.1% at 772.25.

Within major European markets, the German DAX 30 ended down 0.6% and the French CAC 40 down 1.2%

After the European close, US markets continue to trade mixed, with the DJIA down 0.4%, the S&P 500 down 0.2%, and the Nasdaq Composite up 0.2%.

"The (US) data lends more credence to arguments that the Federal Reserve is nearing its mandates and this may bring forward speculation of when the Fed delivers its first rate hike," said Brown Brothers Harriman's Global Head of Currency Strategy Marc Chandler.

The dollar was the best performing currency in the wake of the bumper US GDP reading. The pound fell to the lowest level in six weeks, bottoming at USD1.6885, while the euro fell to its lowest level in more than eight months, bottoming at USD1.3364.

The UK banking sector provided the main downside support to the FTSE 100 after Barclays followed in Royal Bank of Scotland's recent footsteps by releasing first-half results ahead of analyst expectations.

Barclays said it made a GBP3.35 billion adjusted pretax profit in the first six months of 2014, down from a GBP3.59 billion profit in the year before but ahead of the GBP2.96 billion consensus forecast. Barclays also updated as to its progress on capital ratios, with the CET1 ratio increasing to 9.9% and the PRA leverage ratio increasing to 3.4% in the first half.

"The shares have been terrible performers of late so the profit beat and good progress on capital should come as a welcome relief to the market," said Shore Capital analyst Gary Greenwood.

Barclays ended as the top FTSE 100 gainer, up 4.5%, while RBS closed up 2.8%, and Lloyds, which reports its own results on Thursday, closed up 1.0%.

The bank shares envinced little concern over new Bank of England proposals, unveiled Wednesday, to increase individual responsibility and accountability in the banking sector, with changes including a new approval regime for the most senior bankers and new rules on bonuses.

Travis Perkins gained 2.7% after reporting a rise in pretax profit to GBP153.7 million in the first half, up 14% from the previous year, with the company citing improving market conditions and increased customer confidence. The group's consumer division, which incorporates DIY chain Wickes, saw revenue rise 8.8%.

Pets at Home was the top FTSE 250 gainer, closing up 7.1% after saying like-for-like sales were up 4.1% in the second quarter, boosted by a return to TV advertising and its VIP loyalty scheme. Despite the positive update, which boosted the Pets at Home to 182 pence Wednesday, the stock remains well below its March IPO price of 245p.

Mining stocks weighed on the other end of the market, led lower by Antofagasta, which closed down 4.6% at the bottom of the FTSE 100 after reporting production rates in line with expectations, but also a 16% rise in its net cash costs. Antofagasta has generally underperformed the other copper miners so far this year, which analysts attribute to its significant cost inflation.

Although the new sanctions from the EU and the US on Russia over its hand in the crisis in Ukraine are still short on details, the knowledge that they are on the way kept the energy sector in the red, with Royal Dutch Shell, BG Group, and BP down 1.8%, 1.8%, and 0.5%, respectively.

Given Fed Chair Janet Yellen's insistence that future monetary policy is not on a pre-set course and instead is data-dependent, it would not be unreasonable to expect a shift in the tone of the statement given the bumper US GDP reading just released.

While the statement, which follows the FOMC's two-day meeting, will be closely watched for such a change, it is highly unlikely that the central bank will deviate from the path of tapering asset purchases, and another USD10 billion cut is widely expected, which would leave the Fed on course to finish its quantitative easing programme in October.

Given Yellen's recent comment that US social media stocks are looking stretched, she and her colleagues at the FOMC will no doubt have watched with interest as Twitter jumped another 25% at the opening bell Wednesday, after announcing a huge extension of its user base, which grew by 16 million in the second quarter, adding huge future advertising potential.

Looking towards Thursday, while any unexpected commentary from the Federal Reserve has the potential to provide an early driver for markets, European data will be in focus, with unemployment numbers from across the region due throughout the morning and July eurozone CPI released at 1000 BST.

Another busy day in the UK corporate calendar Thursday brings interim results from Lloyds Banking Group, as well as its recently spun-off retail arm TSB Group. While it's the first update from TSB since its late June flotation, the expectations for Lloyds has been raised by the strong results reported Wednesday and last Friday by peers Barclays and Royal Bank of Scotland.

Drinks giant Diageo is scheduled released full-year results Thursday, while other names with interim results slated include BG Group, Centrica, AstraZeneca, BAE Systems, Rolls-Royce, Weir Group, Countrywide, and Intu Properties.

By Jon Darby; jondarby@alliancenews.com; @jondarby100

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.